TTop stories Read More Kennedy’s mRNA vaccine cancellations sharply criticized by expertsAugust 8, 2025 In a sign of the mRNA field’s recent dynamism, the Alliance for mRNA Medicines doubled its size to…
TTop stories Read More Eli Lilly’s much-anticipated obesity pill falls short of WegovyAugust 8, 2025 Eli Lilly’s investigational obesity pill led to less weight loss in a late-stage trial than the reductions seen…
TTop stories Read More Trump demands that pharma companies lower drug pricesAugust 1, 2025 President Trump escalated his demands that pharma companies lower U.S. drug prices in line with what other countries…
HHeadlines Read More Senate committee rejects NIH cuts, boosts budget by $400 millionJuly 31, 2025 WASHINGTON — Senators from both parties endorsed a $400 million increase to the budget of the National Institutes…
HHeadlines Read More White House blocks NIH from awarding any research grantsJuly 30, 2025 Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT…
TTop stories Read More NIH is shrinking the number of research grants it fundsJuly 30, 2025 Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT…
TTop stories Read More Vinay Prasad departs FDA | STATJuly 30, 2025 Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
TTop stories Read More FDA clears way for Sarepta Therapeutics to use Duchenne drug in some patientsJuly 29, 2025 Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
TTop stories Read More As Sarepta, FDA tangle over Duchenne therapy, families are caught in the middleJuly 24, 2025 Jennifer Hill Blair recognized the Cincinnati number on her buzzing phone and slipped out of the school meeting,…
TTop stories Read More Sarepta Therapeutics’ Elevidys faces ‘arduous’ path back to marketJuly 22, 2025 Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
TTop stories Read More FDA rejects Replimune skin cancer therapyJuly 22, 2025 Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
TTop stories Read More Sarepta Therapeutics’ Duchenne therapy crisis has a clear lessonJuly 21, 2025 In a matter of a few days last week, Sarepta Therapeutics announced major layoffs, acknowledged the death of…